Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Main Authors: | Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B |
---|---|
格式: | Journal article |
出版: |
2012
|
相似书籍
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
由: Chakravarthy, U, et al.
出版: (2012) -
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
由: Chakravarthy, U, et al.
出版: (2012) -
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
由: Dakin, H, et al.
出版: (2014) -
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
由: Wen-Jie Wang, et al.
出版: (2015-02-01) -
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
由: Zhe-Li Liu, et al.
出版: (2013-04-01)